Related Experiment Video
Updated: May 11, 2026

Understanding the Development of Compensatory Pathways in a Mutant Malaria Parasite Harbouring Hypomorphic Allele of Plant-Like Kinases
Published on: November 22, 2024
Targeting the vitamin biosynthesis pathways for the treatment of malaria
Thales Kronenberger1, Isolmar Schettert, Carsten Wrenger
1Unit for Drug Discovery, Department of Parasitology, Institute of Biomedical Science, University of São Paulo, Av. Prof. Lineu Prestes 1374, 05508-000 São Paulo-SP, Brazil.
Abstract:
The most severe form of malaria is Malaria tropica, caused by Plasmodium falciparum. There are more than 1 billion people that are exposed to malaria parasites leading to more than 500,000 deaths annually. Vaccines are not available and the increasing drug resistance of the parasite prioritizes the need for novel drug targets and chemotherapeutics, which should be ideally designed to target selectively the parasite. In this sense, parasite-specific pathways, such as the vitamin biosyntheses, represent perfect drug-target characteristics because they are absent in humans. In the past, the vitamin B9 (folate) metabolism has been exploited by antifolates to treat infections caused by malaria parasites. Recently, two further vitamin biosynthesis pathways - for the vitamins B6 (pyridoxine) and B1 (thiamine) - have been identified in Plasmodium and analyzed for their suitability to discover new drugs. In this review, the current status of the druggability of plasmodial vitamin biosynthesis pathways is summarized.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Biosynthesis of Nucleic Acids
Anthelminthic Agents
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

